spacer
home > ict > winter 2018 > proms in practise
PUBLICATIONS
International Clinical Trials

PROMs in Practise

As life expectancy rises and clinical investigations and treatments get ever more effective and complex, expectations of what health systems should deliver in terms of keeping people healthy for longer are, rightly, growing. However, the longstanding challenges of wide variation in access and quality, even within a single system, and spiralling costs are putting an ever greater strain on health systems and pose a risk to continued progress.

Today, healthcare quality is mainly understood in terms of process measures, such as waiting times, length of stay, and discharge rates as well as the unintended consequences or complications of care, such as hospital acquired infections and mortality. These measures are clearly important and need to be measured and managed, but they do not help patients or clinicians understand the actual results of care from the perspective of the patient. This includes information about which patients get better or worse or in what circumstances treatment is successful, whether it is generally done at the right time by a particular doctor or hospital and, if not, why not, how long the benefits last or the relative successes between treatments, doctors, and hospitals. The International Consortium of Health Outcomes Measurement (ICHOM) define ‘outcomes’ as: “The results people care about most when seeking treatment, including functional improvement and the ability to live normal, productive lives” (1). ICHOM was established in 2014 as a partnership between Harvard Business School, Boston Consulting Group, and the Karolinska Institutet in Sweden to set a global standard for outcomes measurement at the level of the clinical condition.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
As life expectancy rises and clinical investigations and treatments get ever more effective and complex, expectations of what health systems should deliver in terms of keeping people healthy for longer are, rightly, growing. However, the longstanding challenges of wide variation in access and quality, even within a single system, and spiralling costs are putting an ever greater strain on health systems and pose a risk to continued progress.

Today, healthcare quality is mainly understood in terms of process measures, such as waiting times, length of stay, and discharge rates as well as the unintended consequences or complications of care, such as hospital acquired infections and mortality. These measures are clearly important and need to be measured and managed, but they do not help patients or clinicians understand the actual results of care from the perspective of the patient. This includes information about which patients get better or worse or in what circumstances treatment is successful, whether it is generally done at the right time by a particular doctor or hospital and, if not, why not, how long the benefits last or the relative successes between treatments, doctors, and hospitals. The International Consortium of Health Outcomes Measurement (ICHOM) define ‘outcomes’ as: “The results people care about most when seeking treatment, including functional improvement and the ability to live normal, productive lives” (1). ICHOM was established in 2014 as a partnership between Harvard Business School, Boston Consulting Group, and the Karolinska Institutet in Sweden to set a global standard for outcomes measurement at the level of the clinical condition.
spacer
Dr Tim Williams
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

NDA Group Releases Data Comparing FDA and EMA Ahead of Annual DIA Europe in Basel

Today NDA Group announced their findings from its fifth annual comparison of drug approvals in Europe and the United States, in preparation for this year’s DIA Europe in Basel, Switzerland. The figures highlight the continued differences between the two regions, and the need for a global approach to drug development to ensure success across both continents.
More info >>

White Papers

Tightening Your Supply Chain Against Counterfeits

World Courier

As today’s global pharmaceutical supply chain grows increasingly longer and more complex, each link provides added opportunity for counterfeiters. While pending regulatory changes promise to tighten the supply chain with respect to production and distribution entities and new packaging technologies will make the identification of counterfeit products easier, the logistics of global distribution remains a weak link. How can the pharmaceutical shipper ensure the security of the supply chain over thousands of miles and extended periods of time when the product is no longer in his possession?
More info >>

 
Industry Events

SAPHEX 2018

1-2 November 2018, Gallagher Convention Centre, Midrand, South Africa

The SAPHEX exhibition and conference is now established as the “go-to” networking and business event for anyone working in the South African pharmaceutical manufacturing industry.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement